SWKH - Acerus amends SWK Funding credit agreement

Acerus Pharmaceuticals ([[ASPCF]]) announces that it has entered into an amended agreement related to its existing credit facility with SWK Funding, a subsidiary of SWK Holdings Corporation ([[SWKH]] -2.1%).The amendments set principal repayment at $1.1M for May 15, 2021 followed by quarterly principal repayments of $600K effective August 15, 2021 and thereafter.Removes all revenue and Adjusted EBITDA covenants for the balance of 2021.Adjusts revenue and Adjusted EBITDA covenants for 2022 and onward.Adjusts the minimum threshold for Consolidated Unencumbered Liquid Assets required to be maintained by the company at $2M effective May 15, 2021.

For further details see:

Acerus amends SWK Funding credit agreement